Sandra Close

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Dante Labs International LLC engages in provision of genomic tests. The company was founded on May 3, 2017 and is headquartered in New York, NY.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.